The pain program COZY - a unique concept for the treatment of chronic pain

Chronic pain is a global scourge that causes enormous human suffering and astronomical costs to society. CombiGene and its partner Zyneyro aim to develop an effective pain treatment that is non-addictive and that does not result in tolerance development.

Pain is one of the biggest challenges in healthcare

Between 6 and 8 % of the world's adult population suffers from severe chronic pain.

Huge costs for society

Annual medical and indirect costs of various diseases in the United States.

Pain: USD 635 billion
Cardiovascular diseases: USD 309 billion
Cancer: USD 243 billion
Diabetes: USD 188 billion

Source: Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. Appendix C. The Economic Cost of Pain in the US. Institute of Medicine (US) Committee on Advancing Pain Research, Care, and Education. Washington (DC): National Academies Press (US); 2011

Today's pharmaceuticals are insufficient

The problem with today's treatments is that they are not specifically developed to treat chronic pain. The pain relief that is achieved therefore often has a number of debilitating side effects such as substance abuse problems, depression, anxiety, fatigue, reduced physical and mental ability.


Peptide treatment of severe chronic pain

The peptide treatment has shown positive effects in various preclinical models. The continued development will focus on conducting the necessary preclinical studies as quickly and efficiently as possible to evaluate safety and toxicology.


Gene therapy treatment for severe chronic pain conditions

A prototype of the AAV vector that acts as a carrier of the genetic material in gene therapy has been developed by Zyneyro and tested in several preclinical models with very good and long-lasting effect. 

The epilepsy project – CG01

CG01 is an AAV-based gene therapy with the potential to improve the quality of life for patients with drug-resistant focal epilepsy for whom there is currently no effective treatment

Latest news

Västra Hamnen publishes initial analysis of CombiGene

CombiGene enters into a license agreement with Spark for the epilepsy project CG01

Stock information

Financial reports

Interim report January – March 2024 for CombiGene AB (publ)

CombiGene AB (publ) publishes annual report for 2023

License agreement with Spark Therapeutics

This year’s annual general meeting is over

CombiGene’s lead project CG01 has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 823282


CombiGene´s project CGT2 is supported by the Eurostars Programme. Project ID: 114714

The peptide-based pain project COZY01 receives Eurostars funding. Project ID: 4408

CombiGene is a member of ATMP Sweden, for more information visit


CombiGene is supporting CCRM Nordic and Jan Nilsson is chairman of the Board of Directors.

Academic collaborations

Within the framework of the epilepsy project CG01, CombiGene has been collaborating with Lund University and the University of Copenhagen for many years. In recent years, CombiGene has also established collaboration regarding the preclinical development of the lipodystrophy project CGT2 with Stockholm University, University Medical Center Hamburg-Eppendorf and University of Michigan Medical School. The pain program COZY originates from academic research at Copenhagen University.